Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04967521 · ClinicalTrials.gov registry record · Phase 3

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

A Phase 3 study of Advanced Dedifferentiated Liposarcoma, sponsored by Sarcoma Alliance for Research through Collaboration.

Active
Registry status
Phase 3
Development phase
108
Enrollment target
9
Study locations

NCT04967521 is a Phase 3 study of Advanced Dedifferentiated Liposarcoma that is active but no longer recruiting, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 108 participants. The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04967521, a Phase 3 study of Advanced Dedifferentiated Liposarcoma, is active but no longer recruiting, sponsored by Sarcoma Alliance for Research through Collaboration.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
108 participants
Enrollment target
9
Study locations

Study Summary

This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.

Interventions

  • DRUG Placebo
  • DRUG Abemaciclib

Study Locations (9)

Colorado

  • University of Colorado Cancer Center, Anschutz Medical Campus - Aurora

Florida

  • Mayo Clinic Florida - Jacksonville

Illinois

  • Northwestern University - Chicago

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Duke University - Durham

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 108 participants
Start Date 2021-11-11
Est. Completion 2026-12
Phase Phase 3

What the Registry Record Tells You About NCT04967521

The ClinicalTrials.gov registry entry for NCT04967521 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarcoma Alliance for Research through Collaboration, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Dedifferentiated Liposarcoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04967521 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Colorado, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT04967521 about?

NCT04967521 is a clinical study titled "SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma". This is a Phase 3 randomized double-blind study of abemaciclib versus placebo. Patients with progression of disease will cross over to open label abemaciclib.

What is the current status of trial NCT04967521?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2021-11-11. Estimated completion is 2026-12.

What conditions does trial NCT04967521 study?

This clinical trial studies the following conditions: Advanced Dedifferentiated Liposarcoma.

What interventions are being tested in trial NCT04967521?

The interventions under investigation include: Placebo (DRUG), Abemaciclib (DRUG).

Who is sponsoring clinical trial NCT04967521?

This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04967521 being conducted?

This trial has 9 study locations across Colorado, Florida, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Dedifferentiated Liposarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.